Therapeutic monoclonal antibodies, such as atezolizumab, nivolumab, durvalumab, and pembrolizumab, targeting the PD1/PDL1 checkpoint, have demonstrated lasting tumor regression across various cancers.84 This evidence concerns the gene CD274 and neoplasm.